An Evaluation of <scp>HER2</scp> Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications
HER2 was frequently expressed in both primary tumors and metastatic LNs in EMPD patients, though heterogeneity was observed. HER2 status should be assessed in both primary and metastatic sites. Disitamab vedotin shows promise for treating HER2-positive advanced EMPD, warranting further study.
Authors
- Cong Yang
- Xingliang Tan (ORCID: https://orcid.org/0000-0002-4015-4982)
- Kai Yao (ORCID: https://orcid.org/0000-0001-8846-5184)
- Yi Tang (ORCID: https://orcid.org/0000-0003-1163-9152)
- Qianghua Zhou (ORCID: https://orcid.org/0000-0001-7483-0478)
- Wensu Wei (ORCID: https://orcid.org/0000-0002-8172-3221)
- Long Huang (ORCID: https://orcid.org/0000-0003-4925-5162)
- Zhicheng Liu (ORCID: https://orcid.org/0000-0002-2332-605X)
- Zhiming Wu (ORCID: https://orcid.org/0009-0009-2686-2200)
- Yanjun Wang (ORCID: https://orcid.org/0000-0001-6121-8706)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial Center for Disease Control and Prevention (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/cam4.71274
- Primary Topic
- Cancer and Skin Lesions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Beijing Xisike Clinical Oncology Research Foundation
- Sun Yat-sen University
- Fundamental Research Funds for the Central Universities
- Basic and Applied Basic Research Foundation of Guangdong Province
- NIH Clinical Center